medigraphic.com
ISSN 1561-2929 (Print)

2016, Number 1

<< Back Next >>

RCAN 2016; 26 (1)

Estado de la adiposidad corporal en sujetos infectados con el virus VIH/sida

Linares GM, Santana PS

Language: Spanish
References: 38
Page: 93-104
PDF size: 410.59 Kb.


ABSTRACT

Rationale: Excessive body weight might be a distinctive trait of HIV-aids infected-people (PVIH/aids) in the antiretroviral era. Excessive boy weight might be related with CD4+ counts. Objective: To determine the association between CD4+ counts and body adiposity of PHIV/aids ambulatorily assisted. Study design: Retrospective, analytical. Material and method: Body Mass Index (BMI), Tricipital skinfold (TSF), Waist circumference (WC), Hip circumference (HC), and Waist-To-Hip ratio (WHR) values as recovered from 217 PVIH/aids living in the province of Pinar del Río, Cuba (Males: 72.4%; Age at the VIH/aids diagnosis: ‹ 30 years: 62.2%; CD4+ counts ‹ 350 cells.mm-3: 32.2%; Antiretroviral therapy: 33.2%) distributed according with antiretroviral therapy (ARVT) and CD4+ count. Results: Anthropometric indicators behaved as follows: BMI: 23.7 ± 4.0 Kg.m-2; TSF: 15.0 /#177; 9.2 mm; WC: 83.4 ± 10.5 cm; HC: 93.8 ± 8.5 cm; WHR: 0.89 ± 0.06; respectively. Distribution of PHIV/aids regarding elevated values of anthropometric indicators was as follows (in descending order): TSF ≥ Cutoff: 88.0%; WHR ≥ Cutoff: 46.5%; BMI ≥ 25 Kg.m-2: 25.8%; WC ≥ Cutoff: 10.1%. Only TSF associated with CD4+ counts, even after adjusting for the effect of ARVT (ORlogistic: 4.14; p ‹ 0.05). On the other hand, WHR associated with ARVT. It is likely that ARVT causes redistribution of body adiposity. Conclusions: The study serie distinguished itself for elevated values of subcutaneous adiposity. In the antiretroviral era, subcutaneous adiposity might anticipate changes occurring in PVIH/aids phenotype.


REFERENCES

  1. López Herce JA. Alteraciones nutricionales en la infección por el virus de la inmunodeficiencia humana (VIH). An Med Interna 2001;18:617-8.

  2. Thiébaut R, Malvy D, Marimoutou C, Davis F; for the Groupe d’Epidémiologie Clinique du Sida en Aquitaine (GECSA). Anthropometric indices as predictors of survival in AIDS adults. Aquitaine cohort, France, 1985-1997. Eur J Epidemiol 2000;16:633-9.

  3. Guenter P, Muurahainen N, Simons G, Kosok A, Cohan GR, Rudenstein R, Turner JL. Relationships among nutritional status, disease progression, and survival in HIV infection. JAIDS J Acquir Immune Deficiency Syndromes 1993;6:1130-8.

  4. Kotler DP, Tierney AR, Wang J, Pierson RN. Magnitude of body cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989; 50:444-7.

  5. Silva M, Skolnik PR, Gorbach SL, Spiegelman D, Wilson IB, Fernández- DiFranco MG, Knox TA. The effect of protease inhibitors on weight and body composition in HIV‐infected patients. AIDS 1998;12:1645-51.

  6. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. The Lancet 2008;372(9635): 293-9.

  7. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL; et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: A cohort analysis from Uganda. Ann Internal Medicine 2011;155:209-16.

  8. Shevitz AH, Knox TA. Nutrition in the era of highly active antiretroviral therapy. Clinical Infectious Diseases 2001;32:1769-75.

  9. Mangili A, Murman DH, Zampini AM, Wanke CA, Mayer KH. Nutrition and HIV infection: Review of weight loss and wasting in the era of highly active antiretroviral therapy from the Nutrition for Healthy Living Cohort. Clinical Infectious Diseases 2006;42:836-42.

  10. Lakey W, Yang LY, Yancy W, Chow SC, Hicks C. From wasting to obesity: Initial antiretroviral therapy and weight gain in HIV-infected persons [Short communication]. AIDS Research Human Retroviruses 2013;29:435-40.

  11. Tate T, Willig AL, Willig JH, Raper JL, Moneyham L, Kempf MC; et al. HIV infection and obesity: Where did all the wasting go? Antiviral Therapy 2012;17: 1281-9.

  12. Crum-Cianflone N, Tejidor R, Medina S, Barahona I, Ganesan A. Obesity among patients with HIV: The latest epidemic. AIDS Patient Care STDs 2008;22: 925-30.

  13. Maia LH, De Mattos AB. Progression to overweight, obesity and associated factors after antiretroviral therapy initiation among Brazilian persons with HIV/AIDS. Nutrición Hospitalaria [España] 2010;25:635-40.

  14. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria associations with insulin resistance, disturbed body fat compartmentalization, elevated Creactive protein, and hypoadiponectinemia. Diabetes Care 2007; 30:113-9.

  15. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG; for the INITIO Trial International Coordinating Committee. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007;21:2445-53.

  16. Leow MKS, Addy CL, Mantzoros CS. Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: Clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 2003;88:1961-76.

  17. Linares Guerra EM, Santana Porbén S. T-Cell number, nutritional status, and HIV: The Cuban experience in the provision of food and nutrition care to people with HIV/AIDS. En: Models of HIV: Lessons to be learned from animal viruses. Health of HIV infected people. Food, nutrition and lifestyle without antiretroviral drugs [Editor: Watson RR]. Volumen 2. Academic Press. London: 2015. Pp 367-387.

  18. Linares M, Bencomo J, Santana S, Barreto J, Ruiz M. Aplicación del método Chang en la evaluación nutricional de individuos VIH/sida. J Bras Doenças Sex Transm 2005;17: 259-64.

  19. Linares Guerra EM, Santana Porbén S, Carrillo Fornés O, León Sánchez MA, Sanabria Negrín JG, Acosta Núñez N, Pla Cruz A, Coniell Linares E. Estado nutricional de las personas con VIH/sida. Su relación con el conteo de las células T CD4+. Nutrición Hospitalaria [España] 2013;28:2197-2207.

  20. Linares Negrín EM, Acosta Núñez NA, Hernández Rodríguez Y, Sanabria Negrín J, Jeréz Hernández E, Plá Crú A. Adiposidad abdominal y riesgo de morbilidad en personas de la provincia de Pinar del Río que viven con VIH/sida. RCAN Rev Cubana Aliment Nutr 2008;18:43-52.

  21. Weiner JA, Lourie JA. Practical Human Biology. Academic Press. London: 1981.

  22. Lohman TG, Roche A, Martorell R. Anthropometric standardization reference manual. Human Kinetics Books. Primera Edición. Champaign [Illinois]: 1988.

  23. Díaz Sánchez ME. Manual de antropometría para el trabajo de nutrición. INHA Instituto de Nutrición e Higiene de los Alimentos. La Habana: 2003.

  24. Shetty PS, James WPT. Body mass index: A measure of chronic energy deficiency in adults. FAO Food and Nutrition Paper number 56. FAO Food and Agriculture Organization. Rome: 1994. Pp 10-11.

  25. Espinosa Borrás A, Martínez González C, Barreto Penié J, Santana Porbén S. Esquema para la evaluación antropométrica del paciente hospitalizado. RCAN Rev Cubana Aliment Nutr 2007; 17:72-89.

  26. WHO World Health Organization. Definition, diagnosis and classification of Diabetes mellitus and its complications. Report of a WHO consultation group. Geneva: 1999.

  27. Santana Porbén S, Martínez Canalejo H. Manual de Procedimientos Bioestadísticos. Segunda Edición. EAE Editorial Académica Española. ISBN-13: 9783659059629. ISBN-10: 3659059625. Madrid: 2012.

  28. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319:670-4.

  29. Kotler DP. Nutritional alterations associated with HIV infection. J Acquired Immune Deficiency Syndromes 1999;25(Suppl):S81-S87.

  30. León MA, Linares EM. La regresión logística binaria como instrumento para la predicción de deterioro inmunológico a partir de indicadores nutricionales en personas con VIH/sida. Investigación Operacional 2014;35:35-48.

  31. Bergman RN, Kim SP, Catalano KJ, Hsu IR, Chiu JD, Kabir M; et al. Why visceral fat is bad: Mechanisms of the metabolic syndrome. Obesity 2006; 14(Suppl 2):S16-S19.

  32. Després JP, Lemieux, I. Abdominal obesity and metabolic syndrome. Nature 2006;444(7121):881-7.

  33. Shlay JC, Sharma S, Grace Peng MS, Gibert CL, Grunfeld C. The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquired Immune Deficiency Syndromes 1999;51:298-307.

  34. Shlay JC, Sharma S, Peng G, Gibert CL, Grunfeld C; for the Terry Beirn Community Programs for Clinical Research on AIDS. Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine. JAIDS J Acquired Immune Deficiency Syndromes 2008;48:53-62.

  35. Mulligan K, Parker RA, Komarow L, Grinspoon SK, Tebas P, Robbins GK; et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. JAIDS J Acquired Immune Deficiency Syndromes 2006;41:590-7.

  36. Saghayam S, Kumarasamy N, Cecelia AJ, Solomon S, Mayer K, Wanke C. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India. Clinical Infectious Diseases 2007;44:295-300.

  37. Mayer KH, Drechsler H, Powderly WG. Switching effective antiretroviral therapy: A review. Clinical Infectious Diseases 2002;35:1219-30.

  38. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N; et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: A randomized trial. JAMA 2002;288: 207-15.




2020     |     www.medigraphic.com